Financial Contrast: Biostage (OTCMKTS:BSTG) vs. T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems (NASDAQ:TTOO) and Biostage (OTCMKTS:BSTG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Earnings and Valuation

This table compares T2 Biosystems and Biostage”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
T2 Biosystems	$7.68 million	0.03	-$50.08 million	($3.89)	0.00
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67

Biostage has lower revenue, but higher earnings than T2 Biosystems. Biostage is trading at a lower price-to-earnings ratio than T2 Biosystems, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

T2 Biosystems has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Biostage has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500.

Insider & Institutional Ownership

23.2% of T2 Biosystems shares are held by institutional investors. 0.0% of T2 Biosystems shares are held by insiders. Comparatively, 15.3% of Biostage shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares T2 Biosystems and Biostage’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
T2 Biosystems	-563.16%	N/A	-174.06%
Biostage	N/A	N/A	-174.43%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for T2 Biosystems and Biostage, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
T2 Biosystems	0	0	0	0	0.00
Biostage	0	0	1	0	3.00

Summary

Biostage beats T2 Biosystems on 6 of the 11 factors compared between the two stocks.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.